[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity
Phio Pharmaceuticals insider Jonathan E. Freeman reported acquisition of 14,700 shares of common stock on 09/11/2025 through restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction Freeman beneficially owns 16,055 shares, a figure that includes other unvested restricted stock units. The filing states the reported amounts were adjusted to reflect prior reverse stock splits. The form was signed by an attorney-in-fact on behalf of the reporting person.
L'insider di Phio Pharmaceuticals, Jonathan E. Freeman, ha riportato l'acquisizione di 14.700 azioni ordinarie il 11/09/2025 tramite unità azionarie vincolate (RSU) che matureranno al primo anniversario annuale dell'assegnazione. Dopo la segnalazione, Freeman detiene beneficiamente 16.055 azioni, cifra che include altre RSU non vestite. La dichiarazione afferma che gli importi riportati sono stati adeguati per riflettere in precedenza scissioni inverse delle azioni. Il modulo è stato firmato da un procuratore in fact per conto della persona che comunica.
Un insider de Phio Pharmaceuticals, Jonathan E. Freeman, informó la adquisición de 14.700 acciones ordinarias el 11/09/2025 mediante unidades de acciones restringidas que vencerán en el primer aniversario del otorgamiento. Tras la operación reportada, Freeman posee de forma beneficiosa 16.055 acciones, cifra que incluye otras RSU no vestidas. La presentación indica que las cantidades reportadas se ajustaron para reflejar desdoblamientos inversos de acciones previos. El formulario fue firmado por un apoderado en nombre de la persona reportante.
Phio Pharmaceuticals의 내부자 Jonathan E. Freeman은 2025년 9월 11일에 제한 주식 단위(RSU)를 통해 보통주 14,700주를 취득했다고 보고했다. RSU는 수여일의 첫 해 기념일에 vesting된다. 보고된 거래 후 Freeman은 16,055주를 실질적으로 보유하게 되며, 이는 아직 vest되지 않은 다른 RSU를 포함한다. 제출서는 과거의 역주식분할을 반영하기 위해 금액이 조정되었다고 명시한다. 양식은 보고자 대신 대리인에 의해 서명됐다.
Un informateur de Phio Pharmaceuticals, Jonathan E. Freeman, a déclaré l'acquisition de 14 700 actions ordinaires le 11/09/2025 par le biais d'unités d'actions restreintes qui vestent au premier anniversaire annuel de l'attribution. Après la transaction déclarée, Freeman détient bénéficiairement 16 055 actions, chiffre incluant d'autres unités d'actions restreintes non acquises. Le dossier indique que les montants déclarés ont été ajustés pour refléter d'anciens splits inverses d'actions. Le formulaire a été signé par un mandataire au nom de la personne déclarant.
Der Insider von Phio Pharmaceuticals, Jonathan E. Freeman, meldete den Erwerb von 14.700 Stammaktien am 11.09.2025 durch Restricted Stock Units, die am ersten jährlichen Jubiläum der Gewährung vesten. Nach der gemeldeten Transaktion besitzt Freeman vorteilhaft 16.055 Aktien, eine Zahl, die auch andere unvestete RSUs einschließt. Das Filing gibt an, dass die gemeldeten Beträge angepasst wurden, um frühere Reverse Stock Splits zu berücksichtigen. Das Formular wurde von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet.
أبلغ شخص ذو صلة بالشركة Phio Pharmaceuticals، جوناثان إي. فريمان، عن شراء 14,700 سهم عادي من خلال وحدات أسهم مقيدة ستصبح قابلة للتحقق عند أول ذكرى سنوية للمنحة. بعد الصفقة المذكورة، يمتلك فريمان بشكل مفيد 16,055 سهمًا، وهو رقم يشمل وحدات أسهم مقيدة إضافية لم تُكتسب بعد. تشير الإيداع إلى أن الأرقام المذكورة قد تم تعديلها لتعكس تقسيمات عكسية سابقة للأسهم. تم توقيع النموذج من قبل وكيل قانوني نيابة عن الشخص المبلغ.
Phio Pharmaceuticals 的内部人士 Jonathan E. Freeman 于 2025-09-11 通过受限股票单位（RSU）购买了 14,700 股普通股，这些 RSU 将在授予后的第一个年度周年日归属。在披露的交易后，Freeman 实益拥有 16,055 股，其中还包含其他尚未归属的 RSU。 filing 表明所报金额已调整以反映此前的反向股票拆分。该表格由代表报告人的代理人签署。
- Director participation in equity compensation aligns management interests with shareholders
- Clear disclosure of vesting schedule (shares vest on first annual anniversary) enhances transparency
- None.
Insights
TL;DR: Director acquired vested-equivalent equity via RSUs; holding remains modest and appears routine.
The Form 4 documents a non-derivative acquisition of 14,700 shares represented by restricted stock units granted to a director, with vesting on the first anniversary of the grant. The post-transaction beneficial ownership is 16,055 shares including other unvested RSUs. The filing notes adjustments for prior reverse stock splits, indicating share counts reflect corporate actions rather than new issuances beyond the RSU grant. This disclosure is standard for Section 16 insiders and provides transparency on director equity compensation without indicating a material change in control or financing.
TL;DR: Disclosure reflects routine director equity grant and standard reporting; no governance red flags disclosed.
The report shows the director received RSUs that convert to common stock on vesting, consistent with typical compensation practices for board members. The filing includes an exhibit for power of attorney and was executed by an attorney-in-fact. The adjustment for reverse stock splits is disclosed, which is appropriate for accurate beneficial ownership reporting. No departures, sales, or unusual transfer terms are described in the document.
L'insider di Phio Pharmaceuticals, Jonathan E. Freeman, ha riportato l'acquisizione di 14.700 azioni ordinarie il 11/09/2025 tramite unità azionarie vincolate (RSU) che matureranno al primo anniversario annuale dell'assegnazione. Dopo la segnalazione, Freeman detiene beneficiamente 16.055 azioni, cifra che include altre RSU non vestite. La dichiarazione afferma che gli importi riportati sono stati adeguati per riflettere in precedenza scissioni inverse delle azioni. Il modulo è stato firmato da un procuratore in fact per conto della persona che comunica.
Un insider de Phio Pharmaceuticals, Jonathan E. Freeman, informó la adquisición de 14.700 acciones ordinarias el 11/09/2025 mediante unidades de acciones restringidas que vencerán en el primer aniversario del otorgamiento. Tras la operación reportada, Freeman posee de forma beneficiosa 16.055 acciones, cifra que incluye otras RSU no vestidas. La presentación indica que las cantidades reportadas se ajustaron para reflejar desdoblamientos inversos de acciones previos. El formulario fue firmado por un apoderado en nombre de la persona reportante.
Phio Pharmaceuticals의 내부자 Jonathan E. Freeman은 2025년 9월 11일에 제한 주식 단위(RSU)를 통해 보통주 14,700주를 취득했다고 보고했다. RSU는 수여일의 첫 해 기념일에 vesting된다. 보고된 거래 후 Freeman은 16,055주를 실질적으로 보유하게 되며, 이는 아직 vest되지 않은 다른 RSU를 포함한다. 제출서는 과거의 역주식분할을 반영하기 위해 금액이 조정되었다고 명시한다. 양식은 보고자 대신 대리인에 의해 서명됐다.
Un informateur de Phio Pharmaceuticals, Jonathan E. Freeman, a déclaré l'acquisition de 14 700 actions ordinaires le 11/09/2025 par le biais d'unités d'actions restreintes qui vestent au premier anniversaire annuel de l'attribution. Après la transaction déclarée, Freeman détient bénéficiairement 16 055 actions, chiffre incluant d'autres unités d'actions restreintes non acquises. Le dossier indique que les montants déclarés ont été ajustés pour refléter d'anciens splits inverses d'actions. Le formulaire a été signé par un mandataire au nom de la personne déclarant.
Der Insider von Phio Pharmaceuticals, Jonathan E. Freeman, meldete den Erwerb von 14.700 Stammaktien am 11.09.2025 durch Restricted Stock Units, die am ersten jährlichen Jubiläum der Gewährung vesten. Nach der gemeldeten Transaktion besitzt Freeman vorteilhaft 16.055 Aktien, eine Zahl, die auch andere unvestete RSUs einschließt. Das Filing gibt an, dass die gemeldeten Beträge angepasst wurden, um frühere Reverse Stock Splits zu berücksichtigen. Das Formular wurde von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet.
FAQ
What transaction did Jonathan E. Freeman report on the PHIO Form 4?
How many PHIO shares does Freeman beneficially own after the transaction?
When do the restricted stock units reported in the PHIO filing vest?
Did the PHIO Form 4 adjust share counts for corporate actions?
Who signed the PHIO Form 4 on behalf of the reporting person?
